A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
作者信息
Richly H, Kupsch P, Passage K, Grubert M, Hilger R A, Kredtke S, Voliotis D, Scheulen M E, Seeber S, Strumberg D
机构信息
University of Essen, West German Cancer Center, Essen, Germany.
出版信息
Int J Clin Pharmacol Ther. 2003 Dec;41(12):620-1. doi: 10.5414/cpp41620.
DOI:10.5414/cpp41620
PMID:14692720
Abstract
摘要
Zotero 插件